FDA approves new, cheaper rival to EpiPen allergy shot
TRENTON, N.J. — U.S. regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed.
The Food and Drug Administration on Thursday approved Adamis Pharmaceuticals Corp.’s product, which should go on sale later this year.
Symjepi is a syringe prefilled with the hormone epinephrine, which helps stop life-threatening allergic reactions from insect stings and bites, foods such as nuts and eggs, or certain medications.
San Diego-based Adamis says its product is easier to use than Mylan’s EpiPen, a spring-loaded syringe filled with a set dose that comes with a training device. Symjepi also is smaller than EpiPen, so it’s easier to fit in a pocket or purse. Most children and adults with severe food or insect allergies carry a device wherever they go and leave a spare at home, school or work.